GGrantIndex
Sort

40,608 grants matching prostate cancer

Western New York Cancer Coalition (WNYC2) Center to Reduce Disparities

$769,068
Willie Underwood · Roswell Park Cancer Institute Corp · U54 · FY2012 · CA

Imaging Immune Modulation in Chimeric Antigen Receptor (CAR) T Cell Therapy

$768,857
Vladimir Ponomarev · Sloan-Kettering Inst Can Research · R01 · FY2020 · CA

Growth Factor Imaging

$768,482
Peter L. Choyke · Basic Sciences · Z01 · FY2007 · CA

MOLECULAR CROSS-TALK: BONE METASTATIC PROSTATE CANCER AND NOCICEPTIVE NEURONS

$768,441
Wake Forest University Health Sciences · · FY2017 · Department of the Army

ROLE OF PEPC, A CIRCULAR RNA ENCODED PROTEIN, IN CASTRATION-RESISTANT PROSTATE CANCER

$768,364
Regents Of The University Of Minnesota · · FY2017 · Department of the Army

MOLECULAR EPIDEMIOLOGY OF PROSTATE CARCINOGENESIS

$768,348
University Of Minnesota Twin Cities · R01 · FY2001 · CA

Developing Informatics Technologies to Model Cancer Gene Regulation

$768,265
Xiaole Shirley Liu · Dana-Farber Cancer Inst · U24 · FY2019 · CA

A NOVEL INHIBITOR OF RIBOSOME BIOGENESIS WITH ANTITUMOR ACTIVITY IN PRECLINICAL MODELS OF PROSTATE CANCER

$768,263
University Of Melbourne · · FY2022 · Department of the Army

Preserving Erectile Function by Quantifying the Nerve-Sparing step of the Robotic Prostatectomy

$768,101
Andrew Hung · University Of Southern California · R01 · FY2022 · CA

Prostate, Lung, Colorectal and Ovarian (PLCO) Screening Trial

$767,995
Douglas J Reding · Marshfield Clinic Research Foundation · N01 · FY2009 · CA

INTERVENTION DEVELOPMENT AND MEASUREMENT

$767,660
Suzanne M Miller · University Of Colorado Denver · P01 · FY2007 · CA

Complementary Adenoviral Vectors for Treatment of Cancer

$767,500
Magnum Therapeutics · R44 · FY2004 · CA

Complementary Adenoviral Vectors for Treatment of Cancer

$767,500
Magnum Therapeutics · R44 · FY2005 · CA

Clinical trials employing cancer vaccine combination therapies

$767,212
James L. Gulley · Division Of Basic Sciences - Nci · ZIA · FY2013 · CA

Cancer Therapy Clinical Trials Using Novel Recombinant Vaccines

$767,212
James L. Gulley · Division Of Basic Sciences - Nci · ZIA · FY2013 · CA

Functional assessment of genes and common genetic risk variants in ovarian cancer

$767,203
Thomas A Sellers · H. Lee Moffitt Cancer Ctr & Res Inst · U19 · FY2012 · CA

Engagement of American Indians of Southwestern Tribal Nations in Cancer Genome Sequencing - Administrative Core

$767,156
Cheryl L Willman · University Of New Mexico Health Scis Ctr · U2C · FY2025 · CA

SAN ANTONIO CENTER OF BIOMARKERS OF RISK FOR PROSTATE CANCER (SABOR)

$767,091
Ian M Thompson · University Of Texas Hlth Science Center · M01 · FY2006 · RR

Molecular Pathology of Cancer

$766,965
Michael R Emmert-Buck · Clinical Sciences · Z01 · FY2007 · CA

Defining mechanisms underlying C9orf72-associated frontotemporal dementia with C. elegans and mammalian models

$766,890
Robert G Kalb · Northwestern University At Chicago · R01 · FY2022 · NS

PROSTATE, LUNG, COLORECTAL AND OVARIAN CANCER SCREENING TRIAL - SCREENING CENTER

$766,675
Douglas Reding · · N01 · FY2007 · CA

Co-evolution of the Reactive Microenvironment in Prostate Cancer Progression

$766,192
David R Rowley · Baylor College Of Medicine · U54 · FY2009 · CA

THE ONCOGENIC PALMITOYL-PROTEIN NETWORK IN PROSTATE CANCER

$766,184
Cedars-Sinai Medical Center · · FY2010 · Department of Defense

GENE-ENVIRONMENT INTERACTION IN PROSTATE CANCER

$766,178
Henry Ford Health System · R01 · FY2003 · ES

Role of Neurotrophins in the Development of the Mammalian Nervous System

$766,137
Lino Tessarollo · Division Of Basic Sciences - Nci · ZIA · FY2012 · CA